Leap Therapeutics News and Activities

Leap Therapeutics is a company listed under the stock ticker LPTX (US).

Acquisition, funding and merger involving Leap Therapeutics.

• Leap Therapeutics has filed its IPO. Its stock ticker will be CYPH. (posted on November 12 2025).
• will change its company name to Cypherpunk Technologies on Nov 13, 2025. (posted on November 12 2025).
• Leap Therapeutics has just announced a $59 Million fundraising (posted on October 17 2025).

View the org chart displaying its 19 main executives

Most searched biographies at Leap Therapeutics

• Doug Onsi, President, Chief Executive Officer
• Thomas Dietz, Director
• Chris Mirabelli, Director

Popular executive movements at Leap Therapeutics

• Khing Oei has joined the company as Chairman of the Board  (posted on November 12 2025).
• Chris Mirabelli who was Chairman of the Board, becomes Director  (posted on November 12 2025).
• Will McEvoy has joined the company as Chief Investment Officer and Director  (posted on November 12 2025).

Create your alert
to follow the executive moves at Leap Therapeutics.

Leap Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Leap Therapeutics

• Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer | Leap Therapeutics, Inc.
• Leap Therapeutics to Host Virtual R&D Day on July 12, 2022 | Leap Therapeutics, Inc.
• Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting | Leap Therapeutics, Inc.
• Leap Therapeutics Reports First Quarter 2022 Financial Results | Leap Therapeutics, Inc.
• Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results | Leap Therapeutics, Inc.
• Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference | Leap Therapeutics, Inc.
• Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients | Leap Therapeutics, Inc.
• Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference | Leap Therapeutics, Inc.
• Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares | Leap Therapeutics, Inc.
• Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants | Leap Therapeutics, Inc.
• View more press releases Close

Social media about Leap Therapeutics

• Leap Therapeutics on Wikipedia, Google News & Yahoo Finance
• Leap Therapeutics on LinkedIn, X (Twitter) & YouTube